MinShan Chen

798 total citations · 2 hit papers
9 papers, 592 citations indexed

About

MinShan Chen is a scholar working on Hepatology, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, MinShan Chen has authored 9 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hepatology, 4 papers in Pathology and Forensic Medicine and 3 papers in Epidemiology. Recurrent topics in MinShan Chen's work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Cancer Mechanisms and Therapy (4 papers) and Liver Disease Diagnosis and Treatment (3 papers). MinShan Chen is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Cancer Mechanisms and Therapy (4 papers) and Liver Disease Diagnosis and Treatment (3 papers). MinShan Chen collaborates with scholars based in China. MinShan Chen's co-authors include QiJiong Li, Li Xu, Ming Shi, Wei Wei, Minke He, Zhongguo Zhou, JingXian Shen, Xiaoping Wu, Ming Zhao and Yong Le and has published in prestigious journals such as Radiology, Clinical Cancer Research and European Journal of Cancer.

In The Last Decade

MinShan Chen

9 papers receiving 588 citations

Hit Papers

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, ... 2019 2026 2021 2023 2019 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
    2019 372 citations Minke He, QiJiong Li et al. JAMA Oncology profile →
  2. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial
    2022 119 citations ZhiCheng Lai, Minke He et al. European Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
MinShan Chen China 7 449 233 167 134 124 9 592
ZhiCheng Lai China 11 351 0.8× 175 0.8× 140 0.8× 113 0.8× 134 1.1× 26 503
Juxian Sun China 13 384 0.9× 72 0.3× 161 1.0× 175 1.3× 82 0.7× 45 546
Yong‐Fa Zhang China 17 397 0.9× 88 0.4× 170 1.0× 194 1.4× 160 1.3× 32 654
Naoki Kamachi Japan 12 303 0.7× 115 0.5× 94 0.6× 95 0.7× 97 0.8× 24 367
Eleonora Terzi Italy 12 530 1.2× 102 0.4× 168 1.0× 309 2.3× 84 0.7× 22 660
Yannan Bai China 10 197 0.4× 50 0.2× 113 0.7× 94 0.7× 131 1.1× 34 418
Che-Chuan Loong Taiwan 10 450 1.0× 51 0.2× 217 1.3× 294 2.2× 89 0.7× 14 614

Countries citing papers authored by MinShan Chen

Since Specialization
Citations

This map shows the geographic impact of MinShan Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by MinShan Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites MinShan Chen more than expected).

Fields of papers citing papers by MinShan Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by MinShan Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by MinShan Chen. The network helps show where MinShan Chen may publish in the future.

Co-authorship network of co-authors of MinShan Chen

This figure shows the co-authorship network connecting the top 25 collaborators of MinShan Chen. A scholar is included among the top collaborators of MinShan Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with MinShan Chen. MinShan Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Zhang, Yaojun, Jinbin Chen, Zhongguo Zhou, et al.. (2025). Transarterial Chemoembolization with Radiofrequency Ablation versus Surgical Resection for Small Late-Recurrence Hepatocellular Carcinoma. Radiology. 314(2). e241096–e241096. 3 indexed citations
2.
Lai, ZhiCheng, JingXian Shen, QiJiong Li, et al.. (2023). Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC). Clinical Cancer Research. 29(24). 5104–5115. 17 indexed citations
3.
Lai, ZhiCheng, Minke He, Yu-Jie Xu, et al.. (2022). Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. European Journal of Cancer. 174. 68–77. 119 indexed citations breakdown →
4.
Zhang, Lihong, Minke He, ZhiCheng Lai, et al.. (2022). Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials. Technology in Cancer Research & Treatment. 21. 2213859277–2213859277. 6 indexed citations
5.
Deng, Qiudi, Xueping Lei, MinShan Chen, et al.. (2021). Triptolide suppresses the growth and metastasis of non-small cell lung cancer by inhibiting β-catenin-mediated epithelial–mesenchymal transition. Acta Pharmacologica Sinica. 42(9). 1486–1497. 41 indexed citations
6.
Luo, Yun, MinShan Chen, Fan Wang, et al.. (2020). Association between dietary patterns and prognosis of hepatocellular carcinoma in the Guangdong liver cancer cohort study. Hepatology Research. 50(10). 1164–1175. 10 indexed citations
7.
He, Minke, QiJiong Li, Ruhai Zou, et al.. (2019). Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion. JAMA Oncology. 5(7). 953–953. 372 indexed citations breakdown →
8.
Peng, Zhenwei, et al.. (2011). Effects of percutaneous radiofrequency ablation and repeat hepatectomy for the treatment of solitary recurrent hepatocellular carcinoma with the diameter no more than 3 cm. Zhōnghuá xiāohuà wàikē zázhì/Zhonghua xiaohua waike zazhi. 10(1). 36–39. 2 indexed citations
9.
Pan, Ke, MinShan Chen, Jianjun Li, et al.. (2010). Decreased expression of XPO4 is associated with poor prognosis in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology. 26(3). 544–549. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by ZhiCheng Lai Breakdown of academic impact, for papers by Juxian Sun Breakdown of academic impact, for papers by Yong‐Fa Zhang Breakdown of academic impact, for papers by Naoki Kamachi Breakdown of academic impact, for papers by Eleonora Terzi Breakdown of academic impact, for papers by Yannan Bai Breakdown of academic impact, for papers by Che-Chuan Loong
Rankless by CCL
2026